Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
AIDX
20/20 Biolabs, Inc.
CAPPED RATING
20/20 Biolabs, Inc. (AIDX) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Momentum (F).
Quantitative Factor Evaluation • Updated
Overall Rating
2.5
/ 5.0
C
Value
B
Factor Score
3.4
/ 5.0
Growth
B+
Factor Score
3.8
/ 5.0
Profitability
C-
Factor Score
2.0
/ 5.0
Momentum
F
Factor Score
0.6
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
N/A
EV / EBITDA
0.0
Rev Growth YoY
36.5%
Gross Margin
31.5%
Price Return 3M
-63.5%
Price Return 12M
-99.2%
Catalyst Signal
0.00
Market Cap
$2.5M
TTM Revenue
$2.0M
Price / Sales
1.2
ROE
-331.2%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B (3.4) | B+ (3.8) | C- (2.0) | F (0.6) | C+ (2.6) | C (2.5) |
| 2026-11-10 | B- (3.0) | B+ (3.8) | C- (2.1) | D- (0.8) | C+ (2.6) | C (2.5) |
| 2026-11-03 | B- (3.0) | B+ (3.8) | C (2.2) | D- (0.9) | C+ (2.7) | C+ (2.5) |
| 2026-10-27 | B- (3.0) | B+ (3.8) | C- (2.1) | D- (0.7) | C+ (2.6) | C (2.5) |
| 2026-10-20 | B- (3.0) | B+ (3.8) | C- (2.1) | D- (0.7) | C+ (2.6) | C (2.5) |
Page
1
of
4